Physician profile
Colin A Ruff
NPI 1174722292
$3,491.29
in general payments reported to CMS, 2019-2025
28 companies · $520 in 2025
The $520 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $143 · 2021: $90.14 · 2022: $460 · 2023: $741 · 2024: $850 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.38 |
| Education | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.52 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Novartis Pharmaceuticals Corporation | $498.20 | 2019-2025 | |
| Leo Pharma INC. | $214.00 | 2022-2025 | Adbry |
| Pfizer INC. | $173.92 | 2023-2025 | |
| Galderma Laboratories, L.P. | $160.98 | 2019-2024 | |
| Incyte Corporation | $159.18 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $148.48 | 2019-2025 | Winlevi, Ilumya |
| Amgen INC. | $133.72 | 2022-2025 | Otezla |
| Celgene Corporation | $110.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.31 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $100.31 | 2019 | |
| Genzyme Corporation | $99.96 | 2019-2025 | |
| Almirall LLC | $85.74 | 2019 | |
| Lilly USA, LLC | $84.90 | 2022 | |
| Dermavant Sciences, INC. | $66.42 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.86 | 2019 | |
| Organon LLC | $32.41 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $32.28 | 2024 | Zoryve |
| Ucb, INC. | $30.29 | 2024-2025 | Bimzelx |
| Organogenesis INC. | $26.66 | 2023 | Puraply |
| Fresenius Kabi USA, LLC | $22.15 | 2023 | |
| Hydrofera LLC | $22.06 | 2025 | Hydrofera Blue |
| Kyowa Kirin, INC. | $18.91 | 2023 | Poteligeo |
| Allergan, INC. | $18.69 | 2022 | |
| Krystal Biotech INC | $16.35 | 2023 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $14.98 | 2020 | |
| Janssen Biotech, INC. | $14.24 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.